ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation

Zheng, Xinting; Luo, Jiamin; Liu, Wei; Ashby, Charles R., Jr.; Chen, Zhe-Sheng*; Lin, Lizhu*广州中医药大学; 1
DRUGS OF TODAY2022-4DOI: 10.1358/dot.2022.58.4.3400573
10被引8阅读
引用收藏
分享

摘要

Sotorasib, a direct inhibitor of the enzyme Kirsten rat sarcoma viral oncogene (KRAS) with the G12C mutation, was approved by the U.S. Food and Drug Administration (FDA), as a second-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) containing the KRAS G12C mutation, on the basis of results of a phase II clinical trial (CodeBreaK100). In this article, we review the mechanism of action of KRAS G12C inhibitors and the latest clinical trials with sotorasib to provide a comprehensive understanding of its efficacy and toxicity. We also review the mechanisms that produce resistance to the KRAS G12C inhibitors and the preclinical research related to combination treatments for KRAS G12C-mutated tumors. Currently, clinical data suggests that sotorasib monotherapy has significant efficacy in NSCLC patients with the KRAS G12C mutation and tolerable toxicity, and it could represent a novel targeted therapy. Additional research will be required to delineate the mechanisms of resistance to sotorasib and determine the efficacy and safety of combination therapy for the treatment of NSCLC containing the KRAS G12C mutation.

学科与关键词

关键词
SotorasibNon-small cell lung cancer (NSCLC)KRAS G12C mutation inhibitorsSolid tumor therapyTargeted cancer therapy
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
DRUGS OF TODAY
发表日期
2022-04
卷期
第 58 卷, 第 4 期
页码
175-185
DOI
10.1358/dot.2022.58.4.3400573
语言
ENGLISH
期刊等级
4区
成果收录
SCIE

作者

  • Z

    Zheng, Xinting (第一作者)

    1 · guangzhou univ chinese med

  • L

    Luo, Jiamin

    1 · guangzhou univ chinese med

查看全部 6 位作者收起作者
  • L

    Liu, Wei

    1 · guangzhou univ chinese med

  • A

    Ashby, Charles R., Jr.

    new

  • C

    Chen, Zhe-Sheng (通讯)

    new

  • L

    Lin, Lizhu (通讯)

    1 · guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417